0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biosimilars And Biosuperiors Market Research Reports

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting - Product Thumbnail Image

Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

  • Newsletter
  • August 2025
  • 4 Pages
  • Global
From
EUR$200USDGBP
South America Biosimilars Market Outlook, 2030 - Product Thumbnail Image

South America Biosimilars Market Outlook, 2030

  • Report
  • May 2025
  • 80 Pages
From
EUR$2,950USDGBP
Loading Indicator

The Biosimilars and Biosuperiors market is a rapidly growing sector of the pharmaceutical industry. Biosimilars are biologic drugs that are highly similar to an existing biologic drug, while biosuperiors are biologic drugs that are more effective than an existing biologic drug. Biosimilars and biosuperiors are used to treat a variety of conditions, including cancer, autoimmune diseases, and inflammatory diseases. Biosimilars and biosuperiors are developed using advanced biotechnology techniques, such as recombinant DNA technology and monoclonal antibody technology. These drugs are designed to be more cost-effective than their original counterparts, while still providing the same therapeutic benefits. The Biosimilars and Biosuperiors market is expected to continue to grow in the coming years, as more biologic drugs are developed and approved for use. Companies in this market include Amgen, Pfizer, Merck, and Novartis. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more